When treating cancer, please don't forget hepatitis B

Oncologist

Volumn 15, Issue 8, 2010, Pages 826-829

  King, Lindsay Y ^a,c   Chung, Raymond T ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; HBV; Hepatitis b; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; PACLITAXEL; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; ECHOGRAPHY; ENDOMETRIUM CANCER; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LARGE CELL LYMPHOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LOOSE FECES; MALE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

ADULT; AGED; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; VIRUS ACTIVATION;

EID: 77956833756     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0282     Document Type: Article

References (24)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-1500.
3. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
4. Xunrong L, Yan AW, Liang R et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001;11:287-299.
5. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447-449.
6. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
7. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999; 81:69-74.
8. Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. J Med Virol 2003;70:553-561.
9. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311.
10. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:Aprospective study of 626 patients with identification of risk factors. J Med Virol 2000;62: 299-307.
11. Tur-Kaspa R, Laub O. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J Hepatol 1990;11:34-36.
12. Hsu CH, Hsu HC, Chen HL et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004;24:3035-3040.
13. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
14. Rossi G, Pelizzari A, Motta M et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
15. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
16. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325.
17. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709.
18. Dai MS, Wu PF, Shyu RY et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-546.
19. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
20. Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008;47:844-853.
21. Loomba R, Rowley A, Wesley R et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
22. Katz LH, Fraser A, Gafter-Gvili A et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat 2008;15:89-102.
23. Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference statement: Management of hepatitis B. Ann Intern Med 2009;150:104-110.
24. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507-539.